Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catalyst PharmaceuticalsCPRX +0.02%70 EV-to-OCF is 14.90 as of Sep. 02, 2026, which is 52% above its 10-year median of 9.82. GuruFocus rates CPRX with a GF Score™ of 70/100 and a GF Value™ of $25.01 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,407 Biotechnology companies, Catalyst Pharmaceuticals ranks worse than 86.28% on this metric.
The historical rank and industry rank for Catalyst Pharmaceuticals's EV-to-OCF or its related term are showing as below:
CPRX'
s EV-to-OCF Range Over the Past 10 Years
Min: -69.47 Med: 9.82 Max: 37.51
Current: 14.9
During the past 13 years, the highest EV-to-OCF of Catalyst Pharmaceuticals was 37.51. The lowest was -69.47. And the median was 9.82.
CPRX's EV-to-OCF is ranked worse than 86.28% of 1407
companies
in the Biotechnology industry
Industry Median: -3.7
vs CPRX: 14.90
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Catalyst Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Catalyst Pharmaceuticals's share price for today is $31.49.
Catalyst Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.740.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Catalyst Pharmaceuticals EV-to-OCF Related Terms
Catalyst Pharmaceuticals EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Catalyst Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's EV-to-OCF falls into.
Catalyst Pharmaceuticals's current Enterprise Value is $3,101.7 Mil.
Catalyst Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $208.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalyst Pharmaceuticals (CPRX) has a EV-to-OCF of 14.90 as of Sep. 02, 2026. This is 52% above median its historical median of 9.82. According to the industry distribution chart, Catalyst Pharmaceuticals ranks #1214 out of 1407 companies in the Biotechnology industry, placing it in the top 86.3%.
Is Catalyst Pharmaceuticals' EV-to-OCF too high?
Catalyst Pharmaceuticals' current EV-to-OCF of 14.90 is 52% above median its 10-year median of 9.82. Based on the distribution chart, Catalyst Pharmaceuticals ranks #1214 out of 1407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Catalyst Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' EV-to-OCF compare to PBLS and ELVN?
According to the Biotechnology industry distribution chart, Catalyst Pharmaceuticals ranks #1214 out of 1407 companies for EV-to-OCF. This places Catalyst Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Catalyst Pharmaceuticals's current EV-to-OCF is 14.90, which is 52% above median its own 10-year median of 9.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (CPRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.01, compared to a current price of $31.49 — trading 25.9% above its estimated fair value. The current EV-to-OCF is 14.90, which is 52% above median its 10-year median of 9.82. Catalyst Pharmaceuticals' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Catalyst Pharmaceuticals (CPRX), the current EV-to-OCF is 14.90 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catalyst Pharmaceuticals (CPRX) Overvalued in 2026?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued.
The current stock price of $31.49 is trading 25.9% above its estimated GF Value™ of $25.01.
GuruFocus considers Catalyst Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for CPRX:
EV-to-OCF: 14.90 (52% above median its 10-year median of 9.82)
GF Value™: $25.01 vs. price of $31.49 (25.9% above fair value)
No single metric tells the full story. See the CPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
70GF Score
Get the complete analysis for CPRX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPRX has been successfully added to your 
